Ocugen Provides Business Update with Third Quarter 2026 Financial Results
Key Highlights
- ➤$84.6 million liquidity expected to extend Ocugen’s cash runway into 2028
- ➤OCU400 receives provisional approval and priority designation in The Bahamas
- ➤OCU400 MENA license offers up to $255 million sales milestones and 22% royalties
- ➤OCU400 Phase 3 liMeliGhT topline data expected in Q1 2027
- ➤OCU410 Phase 3 ArMaDa3 trial begins dosing for geographic atrophy
Expert Statements
Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.”
Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
“As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”
Conference Call and Webcast Today at 8:30 a.m. ET * Received Provisional Approval and Priority Designation for OCU400 in The Bahamas * Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) to coordinate and manage patient care * Progressing site readiness in preparation to accept patients * Advancing toward full approval and potential patient enrollment as early as year-end
* Executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical * Initiated dosing in Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) * Cash, cash equivalents, restricted cash, and short-term investments of $84.6 million as of September 30, 2026; with expected runway into 2028 MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update.
Get started
Create a free account to read the full story.